科睿唯安：最值得关注的肿瘤药物预测：ASCO 2025年关键启示报告（英文版）

The ASCO 2025 Annual Meeting in Chicago was overshadowed by events in Washington, D.C. — tariffs, funding cuts, tensions with Mainland China and the threat of 'Most favored nation' price indexing for prescription drugs among them. But beyond the distant political wrangling, it was a year of striking breakthroughs in the war on cancer as bets on emerging modalities like bispecific antibodies, T-cell engagers, antibody drug conjugates, radioligand therapeutics and gene editing platforms